百奥泰：BAT5906获药物临床试验批准

Core Viewpoint - The company Baiotai (688177.SH) has received approval from the National Medical Products Administration for its investigational drug BAT5906, which targets retinal central vein occlusion-related macular edema (CRVO-ME) and pathological myopia-related choroidal neovascularization (pmCNV) [1] Group 1: Drug Development - BAT5906 is a recombinant humanized monoclonal antibody innovative drug developed and produced by the company, classified as an IgG1 full-length antibody with a molecular weight of 149KDa [1] - The drug specifically binds to human VEGF-A165, inhibiting neovascularization [1] - In vitro models show that BAT5906 can block the binding of VEGF to its corresponding receptors, suppressing endothelial cell proliferation and neovascular formation [1] Group 2: Clinical and Safety Profile - In animal studies, BAT5906 demonstrated a longer serum half-life compared to the Fab fragment structure of Ranibizumab, potentially allowing for longer injection intervals in clinical settings [1] - The drug does not trigger antibody-dependent cell-mediated cytotoxicity (ADCC), suggesting a lower incidence of systemic adverse reactions and potentially safer clinical applications [1]